The blood mSEPT9 is capable of assessing the surgical therapeutic effect and the prognosis of colorectal cancer

Biomark Med. 2018 Sep;12(9):961-973. doi: 10.2217/bmm-2018-0012. Epub 2018 Jul 25.

Abstract

Aim: To investigate the performance of methylated SEPT9 (mSEPT9) in assessing the surgical therapeutic effect and prognosis of colorectal cancer (CRC).

Methods: Blood samples before surgery and 1 and 7 days after surgery were obtained from 120 CRC patients, and mSEPT9 and carcinoembryonic antigen (CEA) assays were performed.

Results: The mean plasma mSEPT9 level showed 57.6-times and 131.1-times decrease 1 day and 7 days after surgery, respectively. In contrast, mean CEA levels showed 2.51-and 2.70-times decrease 1 and 7 days after surgery. 86.7% of patients can be assessed by mSEPT9 while 44.2% can be assessed by CEA. Positive mSEPT9 detection before surgery correlated with higher risk of death after surgery.

Conclusion: mSEPT9 is effective for CRC postsurgical assessment and prognosis prediction.

Keywords: CEA; SEPT9; colorectal cancer; ctDNA; methylation; prognosis; qPCR; septin 9; surgery.

Publication types

  • Clinical Trial
  • Multicenter Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Carcinoembryonic Antigen / blood
  • Colorectal Neoplasms / blood*
  • Colorectal Neoplasms / diagnosis
  • Colorectal Neoplasms / surgery
  • Female
  • Humans
  • Male
  • Methylation
  • Middle Aged
  • Neoplasm Proteins / blood*
  • Prognosis
  • Septins / blood*

Substances

  • Carcinoembryonic Antigen
  • Neoplasm Proteins
  • SEPTIN9 protein, human
  • Septins